Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria

International Journal of Cancer

Volumn 138, Issue 3, 2016, Pages 671-678

  Turner, Natalie ^a,b,c   Wong, Hui Li ^a,c   Templeton, Arnoud ^d   Tripathy, Sagarika ^c   Whiti Rogers, Te ^b   Croxford, Matthew ^e   Jones, Ian ^b   Sinnathamby, Mathuranthakan ^b   Desai, Jayesh ^b   Tie, Jeanne ^a,b,c,e   Bae, Susie ^f   Christie, Michael ^b,c   Gibbs, Peter ^a,b,c,e,f   Tran, Ben ^a,b,c,e  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e WESTERN HEALTH   (Australia)

^f BioGrid Australia   (Australia)

Author keywords

neutrophil to lymphocyte ratio; stage II colon cancer; systemic inflammation; tumour infiltrating lymphocytes

Indexed keywords

AGE; AGED; AMERICAN SOCIETY OF ANESTHESIOLOGISTS SCORE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL DENSITY; CELL INFILTRATION; CHRONIC INFLAMMATORY CELL; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INFLAMMATORY CELL; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; SURVIVAL RATE; ADULT; COLON TUMOR; GENETICS; LYMPHOCYTE; MIDDLE AGED; MISMATCH REPAIR; MORTALITY; NEUTROPHIL; PATHOLOGY; PROGNOSIS;

ADULT; AGED; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; HUMANS; INFLAMMATION; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84955694999     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29805     Document Type: Article

References (37)

1. Andre T, Boni C, Navarro M, et al., Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-16.
2. Benson AB, III, Schrag D, Somerfield MR, et al., American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-19.
3. Chee CE, Meropol NJ., Current status of gene expression profiling to assist decision making in stage II colon cancer. Oncologist 2014; 19: 704-11.
4. Diakos CI, Charles KA, McMillan DC, et al., Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014; 15: e493-e503.
5. Grivennikov SI, Greten FR, Karin M., Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
6. Coussens LM, Werb Z., Inflammation and cancer. Nature 2002; 420: 860-7.
7. Cooper K, Squires H, Carroll C, et al., Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-206.
8. Goh HH, Leong WQ, Chew MH, et al., Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. Anticancer Res 2014; 34: 7407-14.
9. Gooden MJ, de Bock GH, Leffers N, et al., The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
10. Pages F, Berger A, Camus M, et al., Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-66.
11. Mlecnik B, Tosolini M, Kirilovsky A, et al., Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29: 610-8.
12. Jorissen RN, Gibbs P, Christie M, et al., Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin Cancer Res 2009; 15: 7642-7651.
13. Templeton AJ, McNamara MG, Seruga B, et al., Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju124
14. McMillan DC, Canna K, McArdle CS., Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003; 90: 215-19.
15. Canna K, McMillan DC, McKee RF, et al., Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer 2004; 90: 1707-9.
16. Kishi Y, Kopetz S, Chun YS, et al., Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009; 16: 614-22.
17. Guthrie GJ, Roxburgh CS, Farhan-Alanie OM, et al., Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer 2013; 109: 24-8.
18. Mallappa S, Sinha A, Gupta S, et al., Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis 2013; 15: 323-8.
19. Morris M, Platell C, Iacopetta B., Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008; 14: 1413-17.
20. Halama N, Michel S, Kloor M, et al., Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011; 71: 5670-7.
21. Krauthamer M, Rouvinov K, Ariad S, et al., A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncology 2013; 85: 27-32.
22. Chua W, Charles KA, Baracos VE, et al., Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288-95.
23. Popat S, Houlston RS., A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005; 41: 2060-70.
24. Merok MA, Ahlquist T, Royrvik EC, et al., Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol 2013; 24: 1274-82.
25. Klingbiel D, Saridaki Z, Roth AD, et al., Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol 2015; 26: 126-32.
26. Ribic CM, Sargent DJ, Moore MJ, et al., Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-57.
27. Smyrk TC, Watson P, Kaul K, et al., Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 2001; 91: 2417-22.
28. Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, et al., Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001; 48: 360-6.
29. Phillips SM, Banerjea A, Feakins R, et al., Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004; 91: 469-75.
30. Zini L, Patard JJ, Capitanio U, et al., Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma. BJU Int 2009; 103: 894-8.
31. Mayr R, May M, Martini T, et al., Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol 2012; 62: 662-70.
32. Australian Institute of Health and Welfare & Australasian Association of Cancer Registries 2012. Cancer in Australia: an overview, 2012. Cancer series no. 74, Canberra, Australia: AIHW, 2012.
33. Galon J, Mlecnik B, Bindea G, et al., Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014; 232: 199-209.
34. Yothers G, O'Connell MJ, Lee M, et al., Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol 2013; 31: 4512-19.
35. Salazar R, Roepman P, Capella G, et al., Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29: 17-24.
36. Maak M, Simon I, Nitsche U, et al., Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg 2013; 257: 1053-8.
37. Gray RG, Quirke P, Handley K, et al., Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011; 29: 4611-19.